Vivek Gupta

  1. Home
  2. Academics
  3. Our Faculty
  4. Vivek Gupta
Associate Dean for Graduate Education and ResearchAssociate Professor, Pharmaceutical Sciences
Pharmaceutical Sciences
College of Pharmacy and Health Sciences
PhD, Pharmaceutical Sciences, Texas Tech University Health Sciences Center (2010)BS, Pharmaceutical Sciences, Jamia Hamdard (University) (2003)Post-Doctoral Training: Department of Chemical Engineering, University of California Santa Barbara (2011-2013)

LinkedIn Profile

Research Website

Dr Vivek Gupta serves as Associate Dean of Graduate Education & Research, and an associate professor of pharmaceutical sciences at College of Pharmacy & Health Sciences. Before joining St. John’s University in September 2016, Dr Gupta was an assistant professor of pharmaceutics at Keck Graduate Institute School of Pharmacy in Claremont, CA (2013-2016). 

Dr Gupta's is an experienced pharmaceutical researcher with interests in developing novel therapies for respiratory disorders. His expertise lies in the fields of novel drug discovery and repurposing, and non-invasive delivery of small and macromolecules via oral and inhalation routes. He also has significant research interest in the fields of pharmaceutical scalability, and nano-repurposing. Diseases of interest include lung cancer, pulmonary fibrosis, pulmonary hypertension, and mesothelioma. 

Dr. Gupta’s lab at St. John’s is very well-equipped with the most updated formulation development and analytical equipment; and is consistently funded by federal and pharmaceutical industry research grants. Dr. Gupta’s research group has published >95 high-impact publications in peer reviewed journals like Journal of Controlled Release, Materials Science & Engineering C, Drug Discovery Today, Pharmaceutical Research to name a few. Dr. Gupta also serves on editorial boards of many peer-reviewed journals including PLOS One, Pharmaceutical Research, International Journal of Molecular Sciences, to name a few; and is also involved in national pharmaceutical organizations including AAPS and CRS.

Multiple technologies and therapies developed by Dr. Gupta’s group have been patented and are at various stages of preclinical/clinical development. Dr. Gupta is also the current chapter adviser for St. John’s-AAPS Student Chapter; and is organizer of Annual Charles Jarowski Symposium in Pharmaceutical Sciences. 

Teaching Interests:

Pharmaceutics, Pharmacokinetics, Pharmaceutical Compounding, Targeted Drug Delivery, Pharmaceutical Analysis


Research Interests:

Inhalation, Pulmonary delivery, Rare Diseases, Pharmaceutical scalability, Respiratory diseases, Drug Repurposing and Repositioning, Mesothelioma, Pulmonary hypertension, Pulmonary fibrosis, Lung cancer


Courses Taught:

Undergraduate

BMS 1000 SEMINARS IN BIOMEDICAL SCIENCES

PHS 4601 EXTEMPORANEOUS COMPOUNDING

PHS 4602 BIOPHA & BASIC PHARMACOKINETICS

PHS 3601 PHARMACEUTICS – I

PHS 3151 CALCULATIONS IN PHARMACY PRACTICE

Graduate

IPP 250 TARGETED DRUG DELIVERY SYSTEMS

IPP 233 INDUSTRIAL PHARM JOURNAL CLUB

PHS 256 PHARMACEUTICAL ANALYSIS

 

Current Lab Personnel:

Dnyandev Gadhave, PhD – Postdoctoral Fellow

Mural Quadros – PhD Candidate

Meghana Mokashi – PhD Candidate

Mimansa Goyal – PhD Candidate

Akanksha Ugale – PhD Student

Zia Uddin Masum – PhD Student

Sravani Ravula – PhD Student

 

Select Publications

Journal Articles

Selected Publications (2020 onwards)

For full list, visit PUBMED or GOOGLE SCHOLAR (>4,700 Citations, H-index – 39)

 

  1. Gadhave DG, Quadros M, Ugale AR, Goyal M, Gupta V* (2023). A Nanoemulgel for Nose-to-Brain Delivery of Quetiapine – QbD-Enabled Formulation Development & In-vitro Characterization. International Journal of Pharmaceutics (Accepted Oct 29, 2023).

  2. Goyal M, Tulsyan G, Kanabar DD, Chavan T, Muth A, Gupta V* (2023). Poly Vinyl Pyrrolidone (PVP) based Inhaled Delivery Carriers for Olaparib for Non-Small Cell Lung Cancer (NSCLC) Treatment. Journal of Drug Delivery Science & Technology (Accepted July 15, 2023).

  3. Chauhan G, Wang X, Yousry C, Gupta V* (2023). Scalable Production and In-vitro Efficacy of Inhaled Erlotinib Nano-emulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC). Pharmaceutics 15(3):996.

  4. Parvathaneni V, Shukla SK, Gupta V* (2023). Development and Characterization of Folic Acid Conjugated Amodiaquine-loaded Nanoparticles – Efficacy in Cancer Treatment. Pharmaceutics 15(3):1001.

  5. Quadros M, Gupta V* (2023). Updated Landscape of Inhaled Medications to Combat COVID-19. Therapeutic Delivery 14(1):5-9.

  6. Wang X, Chauhan G, Tacderas AL, Muth A, Gupta V* (2023). Surface-Modified Inhaled Microparticle-encapsulated Celastrol for Enhanced Efficacy in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences 24(6):5204.

  7. Parvathaneni V, Chilamakuri R, Kulkarni NS, Baig NF, Agarwal S, Gupta V* (2022). Exploring Amodiaquine’s Repurposing Potential in Breast Cancer Treatment – Assessment of In-vitro Efficacy & Mechanism of Action. International Journal of Molecular Sciences 23(19):11455.

  8. Sarvepalli S, Parvathaneni V, Chauhan G, Shukla SK, Gupta V* (2022). Inhaled Indomethacin-loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research (Available online Sept 15, 2022).

  9. Parvathaneni V, Chilamakuri R, Kulkarni NS, Wang X, Agarwal S, Gupta V* (2022). Repurposing Clofazimine for Malignant Pleural Mesothelioma Treatment – In-vitro Assessment of Efficacy and Mechanism of Action. Life Sciences 306:Oct 2022:120843.

  10. Shukla SK, Nguyen V, Goyal M, Gupta V* (2022). Cationically Modified Inhalable Nintedanib Niosomes: Enhancing Therapeutic Activity Against Non-Small Cell Lung Cancer. Nanomedicine (Available online Aug 25, 2022).

  11. Kanabar D, Goyal M, Kane E, Chavan T, Kabir A, Wang X, Shukla S, Almasri J, Goswami S, Osman G, Kokolis M, Spratt D, Gupta V, Muth A* (2022). Small Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer. Journal of Medicinal Chemistry 65(13):8975-8997.

  12. Kulkarni NS,Gupta V* (2022). Repurposing Therapeutics for Malignant Pleural Mesothelioma (MPM) – Updates on Clinical Translation and Future Outlook. Life Sciences 304:Sept 2022:120716.

  13. Kulkarni NS, Chauhan G, Goyal M, Sarvepalli S, Gupta V* (2022). Development of Gelatin Methacrylate (GelMa) Hydrogels for Versatile Intracavitary Applications: In-vitro Characterization and Ex-vivo Performance Assessment. Biomaterials Science (Invited article for Biomaterials Science Emerging Investigators Series) 10:4492-4507.

  14. Shukla SK, Sarode A, Wang X, Mitragotri S, Gupta V* (2022). Particle Shape Engineering for Improving Safety and Efficacy of Doxorubicin – A Case Study of Rod-Shaped Carriers in Resistant Small Cell Lung Cancer. Biomaterials Advances (Previously Materials Science & Engineering C) 137:212850.

  15. Sawant SS, Patil SM, Shukla SK, Kulkarni NS, Gupta V, Kunda NK (2021). Pulmonary Delivery of Osimertinib Liposomes for Non-Small Cell Lung Cancer Treatment: Formulation Development and In-vitro Evaluation. Drug Delivery and Translational Research 12:2474-2487.

  16. Parvathaneni V, Shukla SK, Kulkarni NS, Gupta V* (2021). Development and Characterization of Inhalable Transferrin Functionalized Amodiaquine Nanoparticles – Efficacy in Non-small Cell Lung Cancer (NSCLC) Treatment. International Journal of Pharmaceutics 608:121038.

  17. Shukla SK, Sarode A, Kanabar DD, Muth A, Kunda NK, Mitragotri S, Gupta V* (2021). Bioinspired Particle Engineering for Non-invasive Drug Delivery to the Lungs. Materials Science & Engineering C 128:112324.

  18. Parvathaneni V, Elbatanony R, Goyal M, Chavan T, Vega N, Kolluru S, Muth A, Gupta V*, Kunda NK* (2021). Repurposing Bedaquiline for Effective Non-small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-based Molecular Inclusion Complexes. International Journal of Molecular Sciences (Accepted April 27, 2021).

  19. Kulkarni NS, Vaidya B, Gupta V* (2021). Nano-synergistic Combination of Erlotinib and Quinacrine for Non-Small Cell Lung Cancer (NSCLC) Therapeutics – Evaluation in Biologically Relevant In-vitro Models. Materials Science and Engineering C 121:Feb 2021:111891.

  20. Parvathaneni V, Elbatanony R, Shukla SK, Kulkarni NS, Kanabar DD, Chauhan G, Ayehunie S, Chen ZS, Muth A, Gupta V*(2020). Bypassing P-glycoprotein Mediated Efflux of Afatinib by Cyclodextrin Complexation – Evaluation of Intestinal Absorption and Anti-Cancer Activity. Journal of Molecular Liquids (Available online November 25, 2020).

  21. Kulkarni NS, Vaidya B, Parvathaneni V, Bhanja D, Gupta V*(2020). Repurposing Quinacrine for Treatment of Malignant Mesothelioma – In-vitro Therapeutic and Mechanistic Evaluation. International Journal of Molecular Sciences 21(17):E6306.

  22. Parvathaneni V, Gupta V* (2020). Utilizing Drug Repurposing against COVID-19 – Efficacy, Limitations and Challenges. Life Sciences 259:118275.

  23. Chauhan G, Shaik AA, Kulkarni NS, Gupta V* (2020). The Preparation of Lipid-Based Drug Delivery Systems using Melt Extrusion. Drug Discovery TodayS1359-6446(20)30330-5.

  24. Wang X, Parvathaneni V, Shukla SK, Kulkarni NS, Muth A, Kunda NK, Gupta V* (2020). Inhalable Resveratrol-Cyclodextrin Complex Loaded Biodegradable Nanoparticles for Enhanced Efficacy against Non-Small Cell Lung Cancer. International Journal of Biological Macromolecules 164:638-650.

  25. Wang X, Parvathaneni V, Shukla SK, Kanabar DD, Muth A, Gupta V* (2020). Cyclodextrin Complexation for Enhanced Stability and Non-invasive Pulmonary Delivery of Resveratrol – Applications in Non-Small Cell Lung Cancer Treatment. AAPS PharmSciTech 21(5):183.

  26. Parvathaneni V, Goyal M, Kulkarni NS, Shukla SK, Gupta V* (2020). Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research 37(7):123.

  27. Parvathaneni V, Kulkarni NS, Chauhan G, Shukla SK, Elbatanony R, Patel BI, Kunda NK, Muth A, Gupta V* (2020). Development of Pharmaceutically Scalable Inhaled Anti-cancer Nanotherapy – Repurposing Amodiaquine for Non-Small Cell Lung Cancer (NSCLC). Materials Science and Engineering C 115:111139.

  28. Shukla SK, Chan A, Parvathaneni V, Gupta V*(2020). Metformin-loaded Chitosomes for Treatment of Malignant Pleural Mesothelioma – A Rare Thoracic Cancer. International Journal of Biological Macromolecules 160:128-141.

  29. Parvathaneni V, Kulkarni NS, Shukla SK, Farrales PT, Kunda NK, Muth A, Gupta V* (2020). Systemic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment. Pharmaceutics 12(3):206.

  30. Shukla SK, Kulkarni NS, Farrales P, Kanabar DD, Parvathaneni V, Kunda NK, Muth A, Gupta V*(2020). Sorafenib Loaded Inhalable Polymeric Nanoparticles against Non-Small Cell Lung Cancer. Pharmaceutical Research 37(3):67.

  31. Shukla SK, Kadry H, Bhatt J, Elbatanony R, Ahsan F, Gupta V* (2020). Statistical Optimization and Validation of a Novel UPLC Method for Estimation of Nintedanib in Rat and Human Plasma. Bioanalysis 12(3):159-174.

  32. Vaidya B, Kulkarni NS, Shukla SK, Parvathaneni V, Chauhan G, Damon JK, Sarode A, Garcia JV, Kunda NK, Mitragotri S, Gupta V* (2020). Development of Inhalable Quinacrine Loaded Bovine Serum Albumin Modified Cationic Nanoparticles: Repurposing Quinacrine for Lung Cancer Therapeutics. International Journal of Pharmaceutics 577(2020):118995.

Current Funding

  1. American Heart Association
  2. Woolsey Pharmaceuticals
  3. PulmoSIM Therapeutics
  4. Stemline Therapeutics